Norris Medicines Ltd Stock Hits 52-Week Low Amidst Continued Downtrend

Price Movement and Market Context

The stock’s latest low of Rs.12.5 was reached on 22 Jan 2026, following six consecutive days of decline. Despite this, the stock managed to gain on the day, outperforming its sector by 5.32%. However, Norris Medicines remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating persistent downward momentum.

In contrast, the Sensex opened higher at 82,459.66 points, gaining 550.03 points (0.67%) but was trading slightly lower at 81,991.39 points (down 0.1%) during the session. The Sensex has experienced a three-week consecutive decline, losing 4.4% over this period. Mid-cap stocks, however, have shown resilience, with the BSE Mid Cap index rising by 0.76% today.

Long-Term Performance and Relative Comparison

Over the past year, Norris Medicines has delivered a return of -41.98%, significantly underperforming the Sensex, which posted a positive return of 7.36% during the same period. The stock’s 52-week high was Rs.24.65, highlighting the extent of the decline from its peak.

Further, the stock has underperformed the BSE500 index over the last three years, one year, and three months, reflecting challenges in both the near and long term.

Fundamental Assessment and Financial Metrics

Norris Medicines currently holds a Mojo Score of 12.0 with a Mojo Grade of Strong Sell, upgraded from Sell as of 30 Jun 2025. The company’s market capitalisation grade stands at 4, reflecting its relatively modest size within the sector.

The company’s financial health is characterised by a negative book value, signalling weak long-term fundamental strength. Net sales have declined at an annual rate of -2.13% over the past five years, while operating profit has remained flat at 0% growth during the same period.

Debt levels are notable, with an average debt-to-equity ratio of 0 times, indicating the company carries debt but not excessively so. However, the company’s earnings metrics have deteriorated, with the latest quarterly PBDIT at a low of Rs.-0.49 crore and PBT less other income at Rs.-0.72 crore. Earnings per share (EPS) for the quarter also hit a low of Rs.-0.73.

Profitability and Valuation Concerns

The stock’s EBITDA remains negative, which contributes to its classification as a risky investment relative to its historical valuation averages. Profitability has declined sharply, with profits falling by 71% over the past year. This decline in earnings has coincided with the stock’s steep price drop, underscoring the challenges faced by the company.

Despite the recent daily gain, the overall trend remains downward, with the stock trading below all major moving averages and continuing to lag behind sector and market benchmarks.

Shareholding Pattern and Market Position

The majority of Norris Medicines’ shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The company operates within the Trading & Distributors sector, which has seen mixed performance in recent months.

While the broader market indices have shown some resilience, Norris Medicines’ stock continues to face headwinds, reflected in its sustained price weakness and fundamental challenges.

Summary of Key Metrics

To summarise, Norris Medicines Ltd’s stock has reached a new 52-week low of Rs.12.5, down from a high of Rs.24.65 within the past year. The company’s financial indicators reveal negative earnings, flat operating profit growth, and a negative book value, contributing to its Strong Sell Mojo Grade. The stock’s performance has lagged significantly behind the Sensex and sector averages, with a one-year return of -41.98% compared to the Sensex’s 7.36% gain.

Despite a slight recovery today, the stock remains below all major moving averages and continues to face valuation and profitability pressures.

Unlock special upgrade rates for a limited period. Start Saving Now →